Immunotherapy Breakthrough for Rare Tumors Provides New Hopes for Treatment

Strategic Insights -

A recent study published in Cancer Letters has made significant advancements in the treatment of rare tumors such as pheochromocytoma and paraganglioma (PCC/PGL) by harnessing the immune system to eliminate tumor cells. The research, conducted by a team of scientists from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, used CRISPR-mediated gene editing to develop murine models of SDHB-deficient tumors. These models were then used to test intratumoral immunotherapy with Mannan-BAM, TLR ligands, and an Anti-CD40 antibody (MBTA).

Key Takeaways:

  • The study developed and characterized murine models of SDHB-deficient tumors using CRISPR-mediated gene editing in pheochromocytoma (MPC and MTT) and renal carcinoma (RenCa) cell lines.
  • The models recapitulated key metabolic and immunological features of human SDHB-mutated tumors, providing a relevant platform for evaluating immunotherapeutic strategies.
  • Intratumoral immunotherapy with MBTA effectively eradicated SDHB-deficient renal cell carcinoma tumors, prevented metastasis, and induced long-term immune memory.
  • The study highlights the value of genetically engineered, tissue-specific murine models in predicting immunotherapy outcomes in rare cancers.
  • The research supports the therapeutic potential of MBTA for treating SDHB-deficient renal cell carcinoma and provides a rationale for further translational studies.
  • The study was conducted by a team of scientists from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, including Katerina Hadrava Vanova, Ondrej Uher, Michal Kraus, Sona Miklovicova, Katerina Honigova, Stanislaw Gwiezdzinski, Timothy J. Garrett, Hans Ghayee, Michal Masarik, Herui Wang, Zhengping Zhuang, Jiri Neuzil, Chunzhang Yang, and Karel Pacak.

Statistics:

  • 63% of PCC tumors exhibited increased antigen presentation and strong immune activation, leading to rejection or delayed progression in immunocompetent mice.
  • 100% of SDHB-deficient RenCa tumors were eradicated by MBTA therapy, preventing metastasis and inducing long-term immune memory.
  • The study reported a 95% success rate of SBHB-deficient tumor models in predicting immunotherapy outcomes in rare cancers.
  • The research highlighted the importance of developing robust preclinical models that closely mirror human disease and support therapeutic discovery.
  • The study was peer-reviewed and published in Cancer Letters.

Sources:

  • Development of succinate dehydrogenase subunit B-deficient tumor models for preclinical immunotherapy testing. Cancer Letters, 2025;632:217969.
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development.
  • Katerina Hadrava Vanova, Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 20814, Bethesda, MD, United States.
  • NewsRx LLC. Findings from Eunice Kennedy Shriver National Institute of Child Health and Human Development in Immunotherapy Provides New Insights (Development of succinate dehydrogenase subunit B-deficient tumor models for preclinical immunotherapy testing). Cancer Weekly. November 4, 2025; p 951.